GSK (GSK) has agreed to acquire oncology company IDRx for up to $1.15 billion, the companies said Monday.
The consideration includes $1 billion in an upfront payment, and up to $150 million in potential regulatory-based milestone payments. GSK will also be responsible for milestone and royalty payments owed to Merck KGaA related to IDRX-42, a treatment candidate for gastrointestinal stromal tumors.
The deal is subject to regulatory clearances, and other customary conditions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。